First of All, Do No Harm: New Directions in EU Antitrust Enforcement Regarding Pharmaceuticals
May 11, 2020
No Comments
The recent Paroxetine and CMA v. Pfizer/Flynn cases confirm the EU approach to pay-for-delay, respectively establish a workable approach to
